You Position: Home > Paper
Recent advances in the study of bioreductive drugs targeted tumor hypoxia
( views:7, downloads:0 )
- Author:
- No author available
- Journal Title:
- ACTA PHARMACEUTICA SINICA
- Issue:
- 7
- DOI:
- 10.3321/j.issn:0513-4870.2009.07.002
- Key Word:
- 低氧;肿瘤;生物还原剂
Abstract： 肿瘤低氧是实体瘤发展过程中必经的过程,是引起肿瘤耐药、复发、侵袭和转移的重要原因.低氧肿瘤细胞对放疗化疗有一定的耐受.肿瘤低氧已成为肿瘤药物治疗的一个重要靶点,近年来,以肿瘤低氧为靶点的生物还原剂在治疗肿瘤方面取得了很人的进展.本文对生物还原剂研究的最新进展予以综述.
- [1]William A. Denny,Michael P. Hay.New and versatile syntheses of 3-alkyl- and 3-aryl-1,2,4-benzotriazine 1,4-dioxides: preparation of the bioreductive cytotoxins SR 4895 and SR 4941[J].2002,43(52).
- [2]Ahn GO,Botting KJ,Patterson AV,etc.Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.[J].2006,71(12).
- [3]Naughton DP.,Threadgill MD.,Ferrer S..H-1 NMR studies on the reductively triggered release of heterocyclic and steroid drugs from 4,7-dioxoindole-3-methyl prodrugs[J].2003,59(19).
- [4]Cerecetto H,Lavaggi ML,Lopez de Cerain A,etc.Novel Cu(II) quinoxaline N(1),N(4)-dioxide complexes as selective hypoxic cytotoxins.[J].2005,40(5).
- [5]Cabrera M,Smircich P,Vieites M,etc.Cytotoxic palladium complexes of bioreductive quinoxaline N1, N4-dioxide prodrugs.[J].2009,17(4).
- [6]Hasinoff BB,Begleiter A.The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells[J].2006,40(9).
- [7]Scott E.Wolkenberg,Dale L.Boger.Mechanisms of in Situ Activation for DNA-Targeting Antitumor Agents[J].2002,102(7).
- [8]Leech D,Kavanagh P,O'Shaughnessy J,etc.Synthesis by radical cyclization and cytotoxicity of highly potent bioreductive alicyclic ring fused [1,2-a]benzimidazolequinones[J].2007,13(11).
- [9]William R. Wilson,David C. Ware,Penelope J. Brothers,etc.Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexes[J].2004,0(4).
- [10]Cho EI,Sartorelli AC,Wilson LD,etc.Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial.[J].2005,61(1).
- [11]Atkinson SJ,Loadman PM,Sutton C,etc.Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry[J].2007,21(7).
- [12]Laurie L.Parker,Louis J.Farrugia,Stephen M.Lacy.A Novel Design Strategy for Stable Metal Complexes of Nitrogen Mustards as Bioreductive Prodrugs[J].2004,47(23).
- [13]Supuran CT.Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.[J].2008,7(2).
- [14]Chowdhury G,Barnes CL,Kotandeniya D,etc.Enzyme-Activated, Hypoxia-Selective DNA Damage by 3-Amino-2-quinoxalinecarbonitrile 1,4-Di-N-oxide.[J].2004,17(11).
- [15]Gellis A,Vanelle P,Kovacic H,etc.Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents.[J].2008,43(9).
- [16]Kotandeniya D,Gates K,Ganley B.Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine).[J].2002,12(17).